Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 251

1.

Prevalence and burden of HBV co-infection among people living with HIV: a global systematic review and meta-analysis.

Platt L, French CE, McGowan CR, Sabin K, Gower E, Trickey A, McDonald B, Ong J, Stone J, Easterbrook P, Vickerman P.

J Viral Hepat. 2019 Oct 11. doi: 10.1111/jvh.13217. [Epub ahead of print]

PMID:
31603999
2.

Hepatitis B virus infection in children and adolescents.

Indolfi G, Easterbrook P, Dusheiko G, Siberry G, Chang MH, Thorne C, Bulterys M, Chan PL, El-Sayed MH, Giaquinto C, Jonas MM, Meyers T, Walsh N, Wirth S, Penazzato M.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):466-476. doi: 10.1016/S2468-1253(19)30042-1. Epub 2019 Apr 11. Review.

PMID:
30982722
3.

Hepatitis C virus infection in children and adolescents.

Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C, Bulterys M, Siberry G, Walsh N, Chang MH, Meyers T, Giaquinto C, Wirth S, Chan PL, Penazzato M.

Lancet Gastroenterol Hepatol. 2019 Jun;4(6):477-487. doi: 10.1016/S2468-1253(19)30046-9. Epub 2019 Apr 11. Review.

PMID:
30982721
4.

Deriving the optimal limit of detection for an HCV point-of-care test for viraemic infection: Analysis of a global dataset.

Freiman JM, Wang J, Easterbrook PJ, Horsburgh CR, Marinucci F, White LF, Kamkamidze G, Krajden M, Loarec A, Njouom R, Nguyen KV, Shiha G, Soliman R, Solomon SS, Tsertsvadze T, Denkinger CM, Linas B.

J Hepatol. 2019 Jul;71(1):62-70. doi: 10.1016/j.jhep.2019.02.011. Epub 2019 Feb 21.

PMID:
30797050
5.

Hepatitis C incidence 3 years after implementation of an educate, test, and treat programme in an Egyptian village.

Shiha G, Soliman R, Mikhail NNH, Easterbrook P.

Lancet Gastroenterol Hepatol. 2019 Jan;4(1):13-14. doi: 10.1016/S2468-1253(18)30336-4. Epub 2018 Dec 6. No abstract available.

PMID:
30527578
6.

Uptake of hepatitis B-HIV co-infection screening and management in a resource limited setting.

Rachel M, Barbara C, Murphy C, Komujuni C, Nyakato P, Ocama P, Lamorde M, Easterbrook P, Ratanshi RP.

Hepatol Med Policy. 2018 Jan 6;3:3. doi: 10.1186/s41124-017-0030-3. eCollection 2018.

7.

An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.

Shiha G, Metwally AM, Soliman R, Elbasiony M, Mikhail NNH, Easterbrook P.

Lancet Gastroenterol Hepatol. 2018 Nov;3(11):778-789. doi: 10.1016/S2468-1253(18)30139-0. Epub 2018 Jul 18. Erratum in: Lancet Gastroenterol Hepatol. 2018 Nov;3(11):e6.

PMID:
30030068
8.

Access to Treatment for Hepatitis B Virus Infection - Worldwide, 2016.

Hutin Y, Nasrullah M, Easterbrook P, Nguimfack BD, Burrone E, Averhoff F, Bulterys M.

MMWR Morb Mortal Wkly Rep. 2018 Jul 20;67(28):773-777. doi: 10.15585/mmwr.mm6728a2.

9.

Economic evaluation of HCV testing approaches in low and middle income countries.

Morgan JR, Servidone M, Easterbrook P, Linas BP.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):697. doi: 10.1186/s12879-017-2779-9. Review.

10.

The future of viral hepatitis testing: innovations in testing technologies and approaches.

Peeling RW, Boeras DI, Marinucci F, Easterbrook P.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):699. doi: 10.1186/s12879-017-2775-0. Review.

11.

Economic evaluations of HBV testing and treatment strategies and applicability to low and middle-income countries.

Nayagam S, Sicuri E, Lemoine M, Easterbrook P, Conteh L, Hallett TB, Thursz M.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):692. doi: 10.1186/s12879-017-2778-x. Review.

12.

The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing.

Tucker JD, Meyers K, Best J, Kaplan K, Pendse R, Fenton KA, Andrieux-Meyer I, Figueroa C, Goicochea P, Gore C, Ishizaki A, Khwairakpam G, Miller V, Mozalevskis A, Ninburg M, Ocama P, Peeling R, Walsh N, Colombo MG, Easterbrook P.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):701. doi: 10.1186/s12879-017-2771-4.

13.

Diagnostic accuracy of serological diagnosis of hepatitis C and B using dried blood spot samples (DBS): two systematic reviews and meta-analyses.

Lange B, Cohn J, Roberts T, Camp J, Chauffour J, Gummadi N, Ishizaki A, Nagarathnam A, Tuaillon E, van de Perre P, Pichler C, Easterbrook P, Denkinger CM.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):700. doi: 10.1186/s12879-017-2777-y. Review.

14.

Methodological challenges in appraising evidence on diagnostic testing for WHO guidelines on hepatitis B and hepatitis C virus infection.

Chou R, Easterbrook P, Hellard M.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):694. doi: 10.1186/s12879-017-2766-1.

15.

Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa.

Coffie PA, Egger M, Vinikoor MJ, Zannou M, Diero L, Patassi A, Kuniholm MH, Seydi M, Bado G, Ocama P, Andersson MI, Messou E, Minga A, Easterbrook P, Anastos K, Dabis F, Wandeler G; IeDEA collaboration.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):706. doi: 10.1186/s12879-017-2768-z. Review.

16.

Optimising diagnosis of viraemic hepatitis C infection: the development of a target product profile.

Ivanova Reipold E, Easterbrook P, Trianni A, Panneer N, Krakower D, Ongarello S, Roberts T, Miller V, Denkinger C.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):707. doi: 10.1186/s12879-017-2770-5.

17.

Diagnostic accuracy of tests to detect hepatitis B surface antigen: a systematic review of the literature and meta-analysis.

Amini A, Varsaneux O, Kelly H, Tang W, Chen W, Boeras DI, Falconer J, Tucker JD, Chou R, Ishizaki A, Easterbrook P, Peeling RW.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):698. doi: 10.1186/s12879-017-2772-3. Review.

18.

Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis.

Lange B, Roberts T, Cohn J, Greenman J, Camp J, Ishizaki A, Messac L, Tuaillon E, van de Perre P, Pichler C, Denkinger CM, Easterbrook P.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):693. doi: 10.1186/s12879-017-2776-z. Review.

19.

Diagnostic accuracy of tests to detect Hepatitis C antibody: a meta-analysis and review of the literature.

Tang W, Chen W, Amini A, Boeras D, Falconer J, Kelly H, Peeling R, Varsaneux O, Tucker JD, Easterbrook P.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):695. doi: 10.1186/s12879-017-2773-2. Review.

20.

WHO guidelines on testing for hepatitis B and C - meeting targets for testing.

Hellard ME, Chou R, Easterbrook P.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):703. doi: 10.1186/s12879-017-2765-2. No abstract available.

21.

Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers.

Reipold EI, Trianni A, Krakower D, Ongarello S, Roberts T, Easterbrook P, Denkinger C.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):702. doi: 10.1186/s12879-017-2769-y.

22.

One or two serological assay testing strategy for diagnosis of HBV and HCV infection? The use of predictive modelling.

Parry JV, Easterbrook P, Sands AR.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):705. doi: 10.1186/s12879-017-2774-1.

23.

Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries.

Ishizaki A, Bouscaillou J, Luhmann N, Liu S, Chua R, Walsh N, Hess S, Ivanova E, Roberts T, Easterbrook P.

BMC Infect Dis. 2017 Nov 1;17(Suppl 1):696. doi: 10.1186/s12879-017-2767-0.

24.

Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial.

Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

Lancet Infect Dis. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3.

25.

Significant rates of risky sexual behaviours among HIV-infected patients failing first-line ART: A sub-study of the Europe-Africa Research Network for the Evaluation of Second-line Therapy trial.

Wanyama JN, Nabaggala MS, Wandera B, Kiragga AN, Castelnuovo B, Mambule IK, Nakajubi J, Kambugu AD, Paton NI, Wanyenze RK, Colebunders R, Easterbrook P.

Int J STD AIDS. 2018 Mar;29(3):287-297. doi: 10.1177/0956462417724707. Epub 2017 Aug 17.

PMID:
28814161
26.

Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.

Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

Lancet HIV. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8.

27.

Diagnosis of viral hepatitis.

Easterbrook PJ, Roberts T, Sands A, Peeling R.

Curr Opin HIV AIDS. 2017 May;12(3):302-314. doi: 10.1097/COH.0000000000000370. Review.

28.

HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.

Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools-Kaloustian K, Bertagnolio S, Easterbrook PJ, Mugyenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team.

J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):e45-e54. doi: 10.1097/QAI.0000000000001285.

29.

Bringing to an end mother-to-child transmission of hepatitis B: A role for quantitative hepatitis B surface antigen?

Dusheiko G, Easterbrook P.

Hepatology. 2016 Nov;64(5):1408-1410. doi: 10.1002/hep.28732. Epub 2016 Aug 27. No abstract available.

PMID:
27452950
30.

Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease.

Nelson NP, Easterbrook PJ, McMahon BJ.

Clin Liver Dis. 2016 Nov;20(4):607-628. doi: 10.1016/j.cld.2016.06.006. Review. Erratum in: Clin Liver Dis. 2017 May;21(2):xiii.

31.

Who to test and how to test for chronic hepatitis C infection - 2016 WHO testing guidance for low- and middle-income countries.

Easterbrook PJ; WHO Guidelines Development Group.

J Hepatol. 2016 Oct;65(1 Suppl):S46-S66. doi: 10.1016/j.jhep.2016.08.002. Review.

PMID:
27641988
32.

Hepatitis C: global epidemiology and strategies for control.

Lanini S, Easterbrook PJ, Zumla A, Ippolito G.

Clin Microbiol Infect. 2016 Oct;22(10):833-838. doi: 10.1016/j.cmi.2016.07.035. Epub 2016 Aug 11. Review.

33.

Facility-Level Factors Influencing Retention of Patients in HIV Care in East Africa.

Rachlis B, Bakoyannis G, Easterbrook P, Genberg B, Braithwaite RS, Cohen CR, Bukusi EA, Kambugu A, Bwana MB, Somi GR, Geng EH, Musick B, Yiannoutsos CT, Wools-Kaloustian K, Braitstein P.

PLoS One. 2016 Aug 10;11(8):e0159994. doi: 10.1371/journal.pone.0159994. eCollection 2016.

34.

Hepatitis C Core Antigen Testing for Diagnosis of Hepatitis C Virus Infection: A Systematic Review and Meta-analysis.

Freiman JM, Tran TM, Schumacher SG, White LF, Ongarello S, Cohn J, Easterbrook PJ, Linas BP, Denkinger CM.

Ann Intern Med. 2016 Sep 6;165(5):345-55. doi: 10.7326/M16-0065. Epub 2016 Jun 21. Review.

35.

Wide variation in estimates of global prevalence and burden of chronic hepatitis B and C infection cited in published literature.

Basnayake SK, Easterbrook PJ.

J Viral Hepat. 2016 Jul;23(7):545-59. doi: 10.1111/jvh.12519. Epub 2016 Mar 30. Review.

PMID:
27028545
36.

Incidence and Prevalence of Opportunistic and Other Infections and the Impact of Antiretroviral Therapy Among HIV-infected Children in Low- and Middle-income Countries: A Systematic Review and Meta-analysis.

B-Lajoie MR, Drouin O, Bartlett G, Nguyen Q, Low A, Gavriilidis G, Easterbrook P, Muhe L.

Clin Infect Dis. 2016 Jun 15;62(12):1586-1594. doi: 10.1093/cid/ciw139. Epub 2016 Mar 21. Review.

37.

HIV and Hepatitis Testing: Global Progress, Challenges, and Future Directions.

Easterbrook P, Johnson C, Figueroa C, Baggaley R.

AIDS Rev. 2016 Jan-Mar;18(1):3-14. Review.

PMID:
26991825
38.

Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa.

Nakanjako D, Kiragga AN, Musick BS, Yiannoutsos CT, Wools-Kaloustian K, Diero L, Oyaro P, Lugina E, Ssali JC, Kambugu A, Easterbrook P.

AIDS. 2016 Jul 31;30(12):1913-22. doi: 10.1097/QAD.0000000000001085.

39.

Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis.

Low A, Gavriilidis G, Larke N, B-Lajoie MR, Drouin O, Stover J, Muhe L, Easterbrook P.

Clin Infect Dis. 2016 Jun 15;62(12):1595-1603. doi: 10.1093/cid/ciw125. Epub 2016 Mar 6. Review.

40.

Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis.

Platt L, Easterbrook P, Gower E, McDonald B, Sabin K, McGowan C, Yanny I, Razavi H, Vickerman P.

Lancet Infect Dis. 2016 Jul;16(7):797-808. doi: 10.1016/S1473-3099(15)00485-5. Epub 2016 Feb 25. Review.

PMID:
26922272
41.

CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa.

Geng EH, Neilands TB, Thièbaut R, Bwana MB, Nash D, Moore RD, Wood R, Zannou DM, Althoff KN, Lim PL, Nachega JB, Easterbrook PJ, Kambugu A, Little F, Nakigozi G, Nakanjako D, Kiggundu V, Ki Li PC, Bangsberg DR, Fox MP, Prozesky H, Hunt PW, Davies MA, Reynolds SJ, Egger M, Yiannoutsos CT, Vittinghoff EV, Deeks SG, Martin JN.

Int J Epidemiol. 2015 Feb;44(1):251-63.

42.

Simplification of antiviral hepatitis C virus therapy to support expanded access in resource-limited settings.

Ford N, Swan T, Beyer P, Hirnschall G, Easterbrook P, Wiktor S.

J Hepatol. 2014 Nov;61(1 Suppl):S132-8. doi: 10.1016/j.jhep.2014.09.019. Epub 2014 Nov 3. Review.

43.

Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models.

Keebler D, Revill P, Braithwaite S, Phillips A, Blaser N, Borquez A, Cambiano V, Ciaranello A, Estill J, Gray R, Hill A, Keiser O, Kessler J, Menzies NA, Nucifora KA, Vizcaya LS, Walker S, Welte A, Easterbrook P, Doherty M, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e35-43. doi: 10.1016/S2214-109X(13)70048-2. Epub 2013 Dec 10.

44.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2014 Jan;2(1):e23-34. doi: 10.1016/S2214-109X(13)70172-4. Epub 2013 Dec 10.

45.

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.

Eaton JW, Menzies NA, Stover J, Cambiano V, Chindelevitch L, Cori A, Hontelez JA, Humair S, Kerr CC, Klein DJ, Mishra S, Mitchell KM, Nichols BE, Vickerman P, Bakker R, Bärnighausen T, Bershteyn A, Bloom DE, Boily MC, Chang ST, Cohen T, Dodd PJ, Fraser C, Gopalappa C, Lundgren J, Martin NK, Mikkelsen E, Mountain E, Pham QD, Pickles M, Phillips A, Platt L, Pretorius C, Prudden HJ, Salomon JA, van de Vijver DA, de Vlas SJ, Wagner BG, White RG, Wilson DP, Zhang L, Blandford J, Meyer-Rath G, Remme M, Revill P, Sangrujee N, Terris-Prestholt F, Doherty M, Shaffer N, Easterbrook PJ, Hirnschall G, Hallett TB.

Lancet Glob Health. 2013 Dec 10;2(1):23-34.

46.

Assessment of second-line antiretroviral regimens for HIV therapy in Africa.

Paton NI, Kityo C, Hoppe A, Reid A, Kambugu A, Lugemwa A, van Oosterhout JJ, Kiconco M, Siika A, Mwebaze R, Abwola M, Abongomera G, Mweemba A, Alima H, Atwongyeire D, Nyirenda R, Boles J, Thompson J, Tumukunde D, Chidziva E, Mambule I, Arribas JR, Easterbrook PJ, Hakim J, Walker AS, Mugyenyi P; EARNEST Trial Team.

N Engl J Med. 2014 Jul 17;371(3):234-47. doi: 10.1056/NEJMoa1311274.

47.

Developing the 2013 WHO consolidated antiretroviral guidelines.

Easterbrook PJ, Irvine CJ, Vitoria M, Shaffer N, Muhe LM, Negussie EK, Doherty MC, Ball A, Hirnschall G.

AIDS. 2014 Mar;28 Suppl 2:S93-100. doi: 10.1097/QAD.0000000000000253. No abstract available.

PMID:
24849484
48.

The impact and cost of the 2013 WHO recommendations on eligibility for antiretroviral therapy.

Stover J, Gopalappa C, Mahy M, Doherty MC, Easterbrook PJ, Weiler G, Ghys PD.

AIDS. 2014 Mar;28 Suppl 2:S225-30. doi: 10.1097/QAD.0000000000000235.

PMID:
24849482
49.

Adoption of national recommendations related to use of antiretroviral therapy before and shortly following the launch of the 2013 WHO consolidated guidelines.

Nelson LJ, Beusenberg M, Habiyambere V, Shaffer N, Vitoria MA, Montero RG, Easterbrook PJ, Doherty MC.

AIDS. 2014 Mar;28 Suppl 2:S217-24. doi: 10.1097/QAD.0000000000000239.

PMID:
24849481
50.

Community and service provider views to inform the 2013 WHO consolidated antiretroviral guidelines: key findings and lessons learnt.

Hsieh AC, Mburu G, Garner AB, Teltschik A, Ram M, Mallouris C, Penazzato M, Shaffer N, Easterbrook PJ, Ball A.

AIDS. 2014 Mar;28 Suppl 2:S205-16. doi: 10.1097/QAD.0000000000000251.

PMID:
24849480

Supplemental Content

Loading ...
Support Center